Similar articles for PMID: 27871301

Year	Number of Results
1999	1
2008	1
2009	1
2010	4
2011	4
2012	5
2013	11
2014	19
2015	18
2016	21
2017	17
2018	12
2019	10
2020	14
2021	3

1

An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the Global aHUS Registry.

Woodward L, Johnson S, Walle JV, Beck J, Gasteyger C, Licht C, Ariceta G; aHUS Registry SAB. Woodward L, et al. Orphanet J Rare Dis. 2016 Nov 21;11(1):154. doi: 10.1186/s13023-016-0537-5. Orphanet J Rare Dis. 2016. PMID: 27871301 Free PMC article. Review.

2

The global aHUS registry: methodology and initial patient characteristics.

Licht C, Ardissino G, Ariceta G, Cohen D, Cole JA, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Schaefer F, Vande Walle J, Frémeaux-Bacchi V. Licht C, et al. BMC Nephrol. 2015 Dec 10;16:207. doi: 10.1186/s12882-015-0195-1. BMC Nephrol. 2015. PMID: 26654630 Free PMC article.

3

The NCI All Ireland Cancer Conference.

Johnston PG, Daly PA, Liu E. Johnston PG, et al. Oncologist. 1999;4(4):275-277. Oncologist. 1999. PMID: 10545862 Free article.

4

Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.

Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N. Mallett A, et al. Intern Med J. 2015 Oct;45(10):1054-65. doi: 10.1111/imj.12864. Intern Med J. 2015. PMID: 26247170

5

Baseline characteristics of patients with atypical haemolytic uraemic syndrome (aHUS): The Australian cohort in a global aHUS registry.

Soraru J, Isbel N, Wong G, Coates PT, Mantha M, Abraham A, Juneja R, Hsu D, Brown F, Bose B, Mudge D, Carroll R, Kausman J, Hughes P, Barbour T, Durkan A, Mount P, Lee D, Larkins N, Ranganathan D, Lim WH. Soraru J, et al. Nephrology (Carlton). 2020 Sep;25(9):683-690. doi: 10.1111/nep.13722. Epub 2020 May 31. Nephrology (Carlton). 2020. PMID: 32378251

6

Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome.

Lapeyraque AL, Frémeaux-Bacchi V, Robitaille P. Lapeyraque AL, et al. Pediatr Nephrol. 2011 Apr;26(4):621-4. doi: 10.1007/s00467-010-1719-3. Epub 2010 Dec 15. Pediatr Nephrol. 2011. PMID: 21161283

7

Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.

Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM. Fakhouri F, et al. Am J Kidney Dis. 2016 Jul;68(1):84-93. doi: 10.1053/j.ajkd.2015.12.034. Epub 2016 Mar 21. Am J Kidney Dis. 2016. PMID: 27012908 Free article. Clinical Trial.

8

Suspected atypical haemolytic uraemic syndrome in two post-partum patients with foetal-death in utero responding to eculizumab.

Chua J, Paizis K, He SZ, Mount P. Chua J, et al. Nephrology (Carlton). 2017 Feb;22 Suppl 1:18-22. doi: 10.1111/nep.12935. Nephrology (Carlton). 2017. PMID: 28176472 Review.

9

Clinical guides for atypical hemolytic uremic syndrome in Japan.

Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H, Kagami S; Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan. Kato H, et al. Pediatr Int. 2016 Jul;58(7):549-55. doi: 10.1111/ped.13044. Pediatr Int. 2016. PMID: 27460397

10

Long-term remission with eculizumab in atypical haemolytic uraemic syndrome.

Carter S, Hewitt I, Kausman J. Carter S, et al. Nephrology (Carlton). 2017 Feb;22 Suppl 1:7-10. doi: 10.1111/nep.12932. Nephrology (Carlton). 2017. PMID: 28176479 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed